Details
Nexium Control provides a course of treatment for relieving symptoms of heartburn, indigestion, and acid reflux. Each pack contains 7 tablets intended for short-term use. These tablets work by reducing stomach acid production, thereby managing discomfort associated with digestive acid-related conditions. It's important to follow the instructions provided for optimal results. GlaxoSmithKline (UK) Trading Limited GSK Consumer Healthcare (IE) Ltd., 980 Great West Road, Brentford, TW8 9GS, U. K. Or: 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.
Show more
Ingredients
Ingredients: Each Gastro-Resistant Tablet contains 20 mg Esomeprazole (as Magnesium Trihydrate). Contains sucrose. See package leaflet for further information. As we are always looking to improve our products, our formulations change from time to time, so please always check the packaging before use.
Directions
Directions for use: Take one tablet once a day. Do not exceed this dose. The tablets should be swallowed whole. Do not chew or crush the tablets. May take 2-3 days for full effect. If your symptoms worsen or do not improve after taking this medicine for 14 days in a row, contact your doctor. Read the package leaflet before use. Oral use. Storage recommendation: Do not store above 30°C. Store in the original package in order to protect from moisture. Keep out of the sight and reach of children.
What is Nexium ControlNexium Control is a proton pump inhibitor (PPI) used to treat acid reflux and heartburn by relieving symptoms such as frequent heartburn, frequent heartburn at the site of heartburn, and the burning sensation in the chest. lifestyle advice.
How to use Nexium ControlAlternate Name:Pharmapure RX Esomep-EZS
Description:Nexium treats gastroesophageal reflux disease (GERD), esophagitis, and stomach ulcers. The generic version of Nexium is esomeprazole magnesium. For a supply of 30 oral tablets of Nexium Delayed-Release Capsules 40 mg is approximately $287. Take advantage of our LowerMyRx discount to receive a typical Nexium discount of up to 80% off of the retail price at participating pharmacies near you.
Dosage Form:Capsule Delayed Release
Administration Route:By mouth
Drug Class:Gastric Acid Secretion Inhibitor, Gastrointestinal Agent
Generic Available:Yes
Strength:20 MG
Warnings:Tell your doctor if you are pregnant or breastfeeding, or if you have kidney disease, liver disease, lupus, vitamin B12 deficiency, or osteoporosis. This medicine may cause the following problems: Kidney problems, including acute tubulointerstitial nephritisIncreased risk of broken bones in the hip, wrist, or spine (more likely if used several times per day or longer than 1 year)Serious skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms (DRESS)LupusFundic gland polyps (abnormal growth in the upper part of your stomach) This medicine can cause diarrhea. Call your doctor if the diarrhea becomes severe, does not stop, or is bloody. Do not take any medicine to stop diarrhea until you have talked to your doctor. Diarrhea can occur 2 months or more after you stop taking this medicine. Tell any doctor or dentist who treats you that you are using this medicine. This medicine may affect certain medical test results. Your doctor will do lab tests at regular visits to check on the effects of this medicine. Keep all appointments. Keep all medicine out of the reach of children. Never share your medicine with anyone. Stomach pain, nausea, vomiting, weight loss, bloody or black stools
Food Warnings:Do not use esomeprazole if you are also using medicines that contain rilpivirine., Some medicines can affect how esomeprazole works. Tell your doctor if you are using any of the following: Atazanavir, cilostazol, diazepam, digoxin, erlotinib, ketoconazole, methotrexate, mycophenolate mofetil, nelfinavir, rifampin, saquinavir, St John's wort, tacrolimus, voriconazoleBlood thinner (including clopidogrel or warfarin)Diuretic (water pill)Iron supplements, This medicine can cause diarrhea. Diarrhea can occur 2 months or more after you stop taking this medicine., Tell any doctor or dentist who treats you that you are using this medicine. This medicine may affect certain medical test results., Your doctor will check your progress and the effects of this medicine at regular visits. Keep all appointments., Keep all medicine out of the reach of children.
You could also get this from some online pharmacy: http://www.novartis.com/us/us/product/309713/nexium-309713-nexium-309713-nexium-309713.html You could also get this from some online pharmacy: https://www.novartis.com/us/websites/us/product/309713/nexium-309713-nexium-309713-nexium-309713.htmlThis background information is not an complete list of certain items to be destroyed or replaced.Common side effects of Nexium may include:
Nexium may lead to a slightly higher risk of certain side effects of PPIs, but these side effects may not require medical attention. For example, this medication can cause stomach bleeding if taken at the wrong time or at high doses. Nexium may also increase the risk of bone pain, fractures, and early-onset osteoporosis.
In rare cases, Nexium may cause more serious side effects like the following:
If you notice any of the above symptoms, contact your healthcare provider promptly.
For more comprehensive information on Nexium and related medications, visit the linked.
Nexium, commonly known by the brand nameesomeprazole, is a prescription medication commonly used to treat frequent heartburn, acid reflux, and to manage GERD. Its cornerstone of therapeutic care may focus on its short half-life, making it suitable for long-term treatment.
Nexium (esomeprazole) belongs to a class of medications called proton pump inhibitors (PPIs). Nexium works by slowing down the production of stomach acid, which helps reduce the symptoms of heartburn and acid reflux. This makes it effective for conditions like heartburn, acid reflux, and to help individuals heal their heartburn-related symptoms.
Nexium should be taken as directed by a healthcare professional, and its dosage can also depend on individual needs. However, it's important to follow the prescribed dosage and duration to achieve the best results. Always consult your healthcare provider for the appropriate dosage and correct usage instructions.
Nexium is a cornerstone of heartburn management, offering ongoing benefits for individuals with Zollinger-Ellison syndrome. By incorporating Nexium into heartburn treatment plans, healthcare providers can:
It's important to note that Nexium is not suitable for everyone, and some individuals may experience side effects. Always consult a healthcare provider for personalized advice and to ensure Nexium is suitable for you.
For individuals who prefer Nexium alternatives, is available from conventional pharmacies or online resources.
The gastro-intestinal (GI) market is poised for steady growth driven by increasing prevalence of inflammatory disorders, including inflammatory bowel disease (IBD), which is a leading cause of death in patients with gastrointestinal disorders. Here’s a comprehensive analysis of the
to help you make informed decisions about your health.
Several factors are driving the growth of IBD, including a higher disease burden, a higher disease prevalence, and obesity. Obesity is a leading cause of IBD, with an estimated 500,000 cases recorded in the United States in 2016, with another million recorded in 2021. These statistics underscore the critical role of obesity in the market.
The rising incidence of IBD globally is a major driver of the market. In 2021, the number of IBD patients in the United States was approximately 500,000, making it the largest per capita IBD incidence in the United States. This increased patient burden ensures a steady growth in the IBD market, driven by improved medical infrastructure, advancements in treatment options, and an aging population.
The GI market is poised for steady growth driven by advancements in IBD treatment, including the availability of over-the-counter (OTC) over-the-counter (Nasal) N-omeprazole (Nomepra) and Zoll Nexium (Ozempic) as well as the rise in weight loss medications like Protonix (dexlansoprazole) and Zepbound (abexibryl) that aim to help patients manage their IBD symptoms. The rising prevalence of IBD in the GI market underscores the importance of treatments like N-omeprazole and Ozempic in IBD management.
The rising number of new drugs in the GI market is another factor that drives the growth. Gastrointestinal diseases, including ulcerative colitis, are becoming a leading cause of IBD, with an estimated 260,000 new cases recorded in 2021, a 41% increase compared with 2009. These figures add up to a substantial market expansion by 2030, driven by the increasing prevalence of IBD and the availability of novel treatments.
The rise in IBD treatment options is a significant factor in the growth of the GI market. Gastrointestinal diseases, including ulcerative colitis and Crohn’s disease, are becoming a leading cause of IBD, with an estimated 650,000 new cases recorded in 2021, a 51% increase compared with 2009. These increases underscore the need for innovative IBD treatment options to address these issues.
Increased patient awareness of IBD is another factor driving the growth of the GI market. Patients are encouraged to report their IBD symptoms to reputable medical professionals, who can assess their overall medical history, current medications, and any pre-existing conditions to determine if they are at high risk for developing IBD. Patients are also encouraged to use dietitians to guide them on their diet and to monitor their weight regularly.
Innovative treatments, such as N-omeprazole and Zoll Nexium, are gaining traction as a treatment option for IBD. Gastrointestinal diseases, including ulcerative colitis and inflammatory bowel disease, are becoming a leading cause of IBD, with an estimated 550,000 new cases recorded in 2021, a 42% increase compared with 2009.
New drug approvals and patient awareness campaigns are driving the growth of IBD treatment options. Gastrointestinal diseases, including ulcerative colitis and inflammatory bowel disease, are becoming a leading cause of IBD, with an estimated 650,000 new cases recorded in 2021, a 42% increase compared with 2009.
Advancements in IBD treatment options are also driving growth.
AstraZeneca has agreed to pay $3.6 million to settle claims that it marketed and sold Nexium in the United States from January 2006 through June 2013, following a clinical trial that concluded Nexium, AstraZeneca’s generic version of the drug, had an increased risk of cardiac events. The settlement provides for a full year of protection for the AstraZeneca brand, and provides for continued marketing exclusivity.
The company also agreed to pay $1.6 million to resolve a class action in the state of Delaware. The suit is filed by Delaware residents who allege that AstraZeneca marketed and sold Nexium in the United States from January 2006 through June 2013. Under the settlement, the company will pay the $3.6 million to resolve the class action. It also agreed to pay $1.6 million to resolve a class action in the state of Delaware.
The settlement gives AstraZeneca a full year of protection for the brand, and provides for continued marketing exclusivity.
Drugs in New Zealand:The company has agreed to pay $1.6 million to resolve a class action in the state of Delaware. Under the settlement, the company will pay the $1.6 million to resolve the class action.
AstraZeneca has agreed to pay $3.6 million to resolve a class action in the state of Delaware.
The company’s share of the settlement comes from a settlement agreement in the federal class action settlement that AstraZeneca made in the state of Delaware.
Patients in New Zealand:Possible Nexium-induced cardiac arrhythmia:AstraZeneca has agreed to pay $3.
Stade de France Pharmacy